MCID: BLD039
MIFTS: 32

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 17 71
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3711
NCIt 49 C39836 C4032
UMLS 71 C0279682

Summaries for Bladder Adenocarcinoma

Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to bladder signet ring cell adenocarcinoma and adenocarcinoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1). The drugs Fluorouracil and Alkylating Agents have been mentioned in the context of this disorder. Affiliated tissues include prostate, colon and kidney.

Related Diseases for Bladder Adenocarcinoma

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Related Disease Score Top Affiliating Genes
1 bladder signet ring cell adenocarcinoma 32.5 KRT7 CDX2
2 adenocarcinoma 30.3 NAPSA KRT7 KRT20 CDX2
3 appendix adenocarcinoma 30.2 KRT7 KRT20 CDX2
4 nephrogenic adenoma 30.2 KRT7 KLK3 AMACR
5 papilloma 30.1 PCNA KRT7 KRT20
6 bladder clear cell adenocarcinoma 30.1 UPK3A NAPSA KRT7 KRT20 CDX2 AMACR
7 linitis plastica 30.1 KRT7 KRT20 CDX2
8 villous adenoma 30.0 KRT20 KLK3 CDX2
9 colorectal adenocarcinoma 29.9 KRT7 KRT20 CDX2
10 signet ring cell adenocarcinoma 29.8 KRT7 KRT20 CDX2
11 inverted papilloma 29.8 PCNA MKI67 KRT7 KRT20
12 adenocarcinoma in situ 29.8 KRT7 KRT20 CDX2
13 rectum adenocarcinoma 29.8 KRT7 KRT20 CDX2
14 tubular adenocarcinoma 29.8 KRT7 KRT20 CDX2
15 cystitis 29.7 UPK3A KRT7 KRT20 CDX2
16 mucinous adenocarcinoma 29.6 KRT7 KRT20 CDX2 AMACR
17 cystitis cystica 29.6 KRT7 KRT20 KLK3 CDX2
18 neurogenic bladder 29.5 UPK3A KLK3
19 transitional cell carcinoma 29.3 UPK3A MKI67 KRT7 KRT20 KLK3
20 suppression of tumorigenicity 12 29.3 AMACR KRT7 KLK3
21 clear cell adenocarcinoma 29.2 NAPSA KRT7 KRT20 KLK3 AMACR
22 endometrial cancer 29.0 UCA1 PCNA MKI67 KRT7 KRT20 KLK3
23 glandular cystitis 28.7 UPK3A UCA1 KRT7 KRT20 CDX2 AMACR
24 lung cancer susceptibility 3 27.7 THBD NAPSA KRT7 KRT20 CDX2 AMACR
25 pelvic lipomatosis 11.3
26 bladder colonic type adenocarcinoma 11.3
27 bladder urachal adenocarcinoma 11.3
28 bladder tubulo-cystic clear cell adenocarcinoma 11.3
29 bladder papillary clear cell adenocarcinoma 11.3
30 bladder hepatoid adenocarcinoma 11.3
31 oral leukoplakia 10.4 PCNA MKI67
32 leukoplakia 10.4 PCNA MKI67
33 ovary neuroendocrine neoplasm 10.4 KRT7 CDX2
34 anal canal paget's disease 10.4 KRT7 CDX2
35 anal paget's disease 10.4 KRT7 CDX2
36 necrotizing sialometaplasia 10.4 MKI67 KRT7
37 ureter adenocarcinoma 10.4 KRT7 CDX2
38 pancreatic foamy gland adenocarcinoma 10.4 KRT7 CDX2
39 adenosquamous colon carcinoma 10.4 KRT7 CDX2
40 nasal cavity adenocarcinoma 10.4 KRT7 CDX2
41 anus adenocarcinoma 10.4 KRT7 CDX2
42 mucinous adenofibroma 10.4 KRT7 CDX2
43 epithelioid trophoblastic tumor 10.4 MKI67 KRT7
44 rectum neuroendocrine neoplasm 10.4 KRT7 CDX2
45 mucinous intrahepatic cholangiocarcinoma 10.4 KRT7 CDX2
46 ovarian seromucinous carcinoma 10.4 KRT7 CDX2
47 anal canal adenocarcinoma 10.4 KRT7 CDX2
48 appendiceal neoplasm 10.4 KRT7 CDX2
49 urethral villous adenoma 10.4 KRT7 KRT20
50 biliary papillomatosis 10.4 KRT7 CDX2

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

Drugs & Therapeutics for Bladder Adenocarcinoma

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3 51-21-8 3385
2 Alkylating Agents Phase 3
3 Mitomycins Phase 3
4
Bevacizumab Approved, Investigational Phase 2 216974-75-3
5
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
6
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
7
Ifosfamide Approved Phase 2 3778-73-2 3690
8
leucovorin Approved Phase 2 58-05-9 6006 143
9
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
10
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
11
Daunorubicin Approved Phase 2 20830-81-3 30323
12
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
13
Vinblastine Approved Phase 2 865-21-4 13342 241903
14
Durvalumab Approved, Investigational Phase 2 1428935-60-7
15
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
16
nivolumab Approved Phase 2 946414-94-4
17
Ipilimumab Approved Phase 2 477202-00-9
18
Gemcitabine Approved Phase 2 95058-81-4 60750
19
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
21 Piritrexim Investigational Phase 2 72732-56-0
22
Rubitecan Investigational Phase 2 91421-42-0
23
Camptothecin Experimental Phase 2 7689-03-4
24 Angiogenesis Inhibitors Phase 2
25
Isophosphamide mustard Phase 2 0
26 topoisomerase I inhibitors Phase 2
27 Antineoplastic Agents, Immunological Phase 2
28 Folic Acid Antagonists Phase 2
29 Vitamin B Complex Phase 2
30 Vitamin B9 Phase 2
31 Folate Phase 2
32 Topoisomerase Inhibitors Phase 2
33 Antibodies, Monoclonal Phase 2
34 Immunoglobulins Phase 2
35 Antibodies Phase 2
36 Anti-Bacterial Agents Phase 2
37 Antibiotics, Antitubercular Phase 2
38 Dermatologic Agents Phase 2
39 Antirheumatic Agents Phase 2
40
Liposomal doxorubicin Phase 2 31703
41 Immunologic Factors Phase 2
42 Anti-Infective Agents Phase 2
43 Antiviral Agents Phase 2
44 Immunosuppressive Agents Phase 2
45 Antimetabolites Phase 2
46 Antimitotic Agents Phase 2
47 Albumin-Bound Paclitaxel Phase 2
48
Pancrelipase Approved, Investigational Phase 1 53608-75-6
49
Sargramostim Approved, Investigational Phase 1 123774-72-1, 83869-56-1
50
Metronidazole Approved Phase 1 443-48-1 4173

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
2 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
3 A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts. Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
4 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
5 Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
6 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
7 A Phase 2 Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Recruiting NCT03747419 Phase 2 Avelumab
8 Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer Recruiting NCT03912818 Phase 2 Carboplatin;Cisplatin;Doxorubicin;Gemcitabine;Methotrexate;Vinblastine
9 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
10 Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years) Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
11 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
12 Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

Anatomical Context for Bladder Adenocarcinoma

MalaCards organs/tissues related to Bladder Adenocarcinoma:

40
Prostate, Colon, Kidney, Lung, Breast, Appendix, Liver

Publications for Bladder Adenocarcinoma

Articles related to Bladder Adenocarcinoma:

(show top 50) (show all 147)
# Title Authors PMID Year
1
Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. 54 61
18789486 2009
2
Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. 54 61
18670358 2008
3
[Expression of CDX2 in urinary bladder and urethra lesions]. 54 61
15074058 2004
4
Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. 54 61
11684954 2001
5
Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. 54 61
10658909 2000
6
Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. 54 61
9522212 1998
7
Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. 61
31496327 2020
8
Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma. 61
31876604 2019
9
Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. 61
31666198 2019
10
Bile spillage and incidental gall bladder adenocarcinoma. 61
31929997 2019
11
Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. 61
31740332 2019
12
Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. 61
31395362 2019
13
A report of orbital metastasis from a urinary bladder adenocarcinoma. 61
31332150 2019
14
Mimickers of urothelial neoplasia. 61
30380401 2019
15
Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression. 61
31317053 2019
16
Non-urothelial carcinomas of the bladder. 61
30565306 2019
17
Primary signet-ring cell carcinoma of the urinary bladder: A report of two cases. 61
31535712 2019
18
Aggressive course in a patient with mucin-producing urothelial-type adenocarcinoma of the prostate: A case report and review of the literature. 61
32027595 2018
19
Treating bladder adenocarcinoma. 61
30687599 2018
20
Incidental Gall Bladder Adenocarcinoma in Cholecystectomy Specimens; A Single Center Experience and Review of the Literature. 61
31049173 2018
21
microRNA‑145 modulates migration and invasion of bladder cancer cells by targeting N‑cadherin. 61
29693148 2018
22
Primary bladder adenocarcinoma: Case report with long-term follow-up. 61
29785373 2018
23
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. 61
27048257 2018
24
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. 61
29203990 2017
25
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. 61
28548125 2017
26
Concordant clear cell "mesonephric" carcinoma of the bladder and lung adenocarcinoma with clear cell features - multiple primaries versus metastatic neoplasms: a case report. 61
28494807 2017
27
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. 61
28511402 2017
28
Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. 61
28056456 2017
29
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. 61
27427223 2016
30
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature. 61
27381065 2016
31
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. 61
27703678 2016
32
Cutaneous metastasis: An unusual presenting feature of urologic malignancies. 61
27453667 2016
33
Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome. 61
27267922 2016
34
[Clinical research of second resection on early stage primary bladder adenocarcinoma and literature review]. 61
27266688 2016
35
Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder. 61
26463756 2016
36
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. 61
27081650 2016
37
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. 61
26955660 2016
38
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. 61
27006847 2016
39
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. 61
27288750 2016
40
[A Case of Bladder Adenocarcinoma with Rectal Metastasis]. 61
26805326 2015
41
Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. 61
25930983 2015
42
Exfoliative erythroderma as a paraneoplastic presentation of adenocarcinoma of the gallbladder. 61
25830047 2015
43
Gall bladder Adenocarcinoma in a Young Girl. 61
26139973 2015
44
Adenocarcinoma of the urinary bladder. 61
26309895 2015
45
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. 61
26421206 2015
46
Serotonin and cancer: what is the link? 61
25601469 2015
47
Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology. 61
25047418 2015
48
En Bloc Robot-assisted Laparoscopic Partial Cystectomy, Urachal Resection, and Pelvic Lymphadenectomy for Urachal Adenocarcinoma. 61
26029004 2015
49
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen. 61
24281125 2015
50
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. 61
25029122 2014

Variations for Bladder Adenocarcinoma

Expression for Bladder Adenocarcinoma

Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for Bladder Adenocarcinoma

GO Terms for Bladder Adenocarcinoma

Sources for Bladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....